|
1
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bellacosa A, Kumar CC, Di Cristofano A and
Testa JR: Activation of AKT kinases in cancer: Implications for
therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Serra V, Markman B, Scaltriti M, et al:
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and
inhibits the growth of cancer cells with activating PI3K mutations.
Cancer Res. 68:8022–8030. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ihle NT, Lemos R Jr, Wipf P, Yacoub A,
Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL and Powis G:
Mutations in the phosphatidylinositol-3-kinase pathway predict for
antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is
a dominant predictor for resistance. Cancer Res. 69:143–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Nicolantonio F, Arena S, Tabernero J,
et al: Deregulation of the PI3K and KRAS signaling pathways in
human cancer cells determines their response to everolimus. J Clin
Invest. 120:2858–2866. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davies BR, Greenwood H, Dudley P, et al:
Preclinical pharmacology of AZD5363, an inhibitor of AKT:
Pharmacodynamics, antitumor activity, and correlation of
monotherapy activity with genetic background. Mol Cancer Ther.
11:873–887. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Janku F, Tsimberidou AM, Garrido-Laguna I,
et al: PIK3CA mutations in patients with advanced cancers treated
with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 10:558–565.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Janku F, Hong DS, Fu S, et al: Assessing
PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR
inhibitors. Cell Rep. 6:377–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bucheit AD and Davies MA: Emerging
insights into resistance to BRAF inhibitors in melanoma. Biochem
Pharmacol. 87:381–389. 2014. View Article : Google Scholar
|
|
11
|
Tartarone A, Lazzari C, Lerose R,
Conteduca V, Improta G, Zupa A, Bulotta A, Aieta M and Gregorc V:
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer.
81:328–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chandarlapaty S: Negative feedback and
adaptive resistance to the targeted therapy of cancer. Cancer
Discov. 2:311–319. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Haruta T, Uno T, Kawahara J, Takano A,
Egawa K, Sharma PM, Olefsky JM and Kobayashi M: A
rapamycin-sensitive pathway down-regulates insulin signaling via
phosphorylation and proteasomal degradation of insulin receptor
substrate-1. Mol Endocrinol. 14:783–794. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O’Reilly KE, Rojo F, She QB, et al: mTOR
inhibition induces upstream receptor tyrosine kinase signaling and
activates Akt. Cancer Res. 66:1500–1508. 2006. View Article : Google Scholar
|
|
15
|
Yu Y, Yoon SO, Poulogiannis G, et al:
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate
that negatively regulates insulin signaling. Science.
332:1322–1326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chandarlapaty S, Sawai A, Scaltriti M,
Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK,
Baselga J and Rosen N: AKT inhibition relieves feedback suppression
of receptor tyrosine kinase expression and activity. Cancer Cell.
19:58–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Muranen T, Selfors LM, Worster DT,
Iwanicki MP, Song L, Morales FC, Gao S, Mills GB and Brugge JS:
Inhibition of PI3K/mTOR leads to adaptive resistance in
matrix-attached cancer cells. Cancer Cell. 21:227–239. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fox EM, Kuba MG, Miller TW, Davies BR and
Arteaga CL: Autocrine IGF-I/insulin receptor axis compensates for
inhibition of AKT in ER-positive breast cancer cells with
resistance to estrogen deprivation. Breast Cancer Res. 15:R552013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagata Y, Lan KH, Zhou X, et al: PTEN
activation contributes to tumor inhibition by trastuzumab, and loss
of PTEN predicts trastuzumab resistance in patients. Cancer Cell.
6:117–127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Berns K, Horlings HM, Hennessy BT, et al:
A functional genetic approach identifies the PI3K pathway as a
major determinant of trastuzumab resistance in breast cancer.
Cancer Cell. 12:395–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eichhorn PJ, Gili M, Scaltriti M, et al:
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib
resistance that is reversed by the mTOR/phosphatidylinositol
3-kinase inhibitor NVP-BEZ235. Cancer Res. 68:9221–9230. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chandarlapaty S, Sakr RA, Giri D, et al:
Frequent mutational activation of the PI3K-AKT pathway in
trastuzumab-resistant breast cancer. Clin Cancer Res. 18:6784–6791.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miller TW, Forbes JT, Shah C, et al:
Inhibition of mammalian target of rapamycin is required for optimal
antitumor effect of HER2 inhibitors against HER2-overexpressing
cancer cells. Clin Cancer Res. 15:7266–7276. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Serra V, Scaltriti M, Prudkin L, et al:
PI3K inhibition results in enhanced HER signaling and acquired ERK
dependency in HER2-overexpressing breast cancer. Oncogene.
30:2547–2557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chakrabarty A, Sánchez V, Kuba MG,
Rinehart C and Arteaga CL: Feedback upregulation of HER3 (ErbB3)
expression and activity attenuates antitumor effect of PI3K
inhibitors. Proc Natl Acad Sci USA. 109:2718–2723. 2012. View Article : Google Scholar :
|
|
26
|
García-García C, Ibrahim YH, Serra V, et
al: Dual mTORC1/2 and HER2 blockade results in antitumor activity
in preclinical models of breast cancer resistant to anti-HER2
therapy. Clin Cancer Res. 18:2603–2612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hickinson DM, Klinowska T, Speake G, et
al: AZD8931, an equipotent, reversible inhibitor of signaling by
epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: A unique
agent for simultaneous ERBB receptor blockade in cancer. Clin
Cancer Res. 16:1159–1169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lehár J, Krueger AS, Avery W, et al:
Synergistic drug combinations tend to improve therapeutically
relevant selectivity. Nat Biotechnol. 27:659–666. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rickles RJ, Tam WF, Giordano TP III, et
al: Adenosine A2A and beta-2 adrenergic receptor agonists: Novel
selective and synergistic multiple myeloma targets discovered
through systematic combination screening. Mol Cancer Ther.
11:1432–1442. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garnett MJ, Edelman EJ, Heidorn SJ, et al:
Systematic identification of genomic markers of drug sensitivity in
cancer cells. Nature. 483:570–575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Elvin P, Palmer A, Womack C, et al:
Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients
with advanced solid tumors. J Clin Oncol. 32(Suppl 5):
25412014.
|
|
32
|
Okuzumi T, Fiedler D, Zhang C, Gray DC,
Aizenstein B, Hoffman R and Shokat KM: Inhibitor hijacking of Akt
activation. Nat Chem Biol. 5:484–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rexer BN and Arteaga CL: Intrinsic and
acquired resistance to HER2-targeted therapies in HER2
gene-amplified breast cancer: Mechanisms and clinical implications.
Crit Rev Oncog. 17:1–16. 2012. View Article : Google Scholar : PubMed/NCBI
|
